1. Home
  2. BWIN vs ACAD Comparison

BWIN vs ACAD Comparison

Compare BWIN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Baldwin Insurance Group Inc.

BWIN

The Baldwin Insurance Group Inc.

N/A

Current Price

$31.97

Market Cap

4.5B

Sector

Finance

ML Signal

N/A

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$20.62

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BWIN
ACAD
Founded
2011
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
4.4B
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
BWIN
ACAD
Price
$31.97
$20.62
Analyst Decision
Hold
Buy
Analyst Count
8
20
Target Price
★ $32.42
$30.53
AVG Volume (30 Days)
★ 1.6M
1.5M
Earning Date
11-17-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 69.12
EPS
N/A
★ 0.20
Revenue
★ $1,504,884,000.00
$726,437,000.00
Revenue This Year
$32.28
$18.71
Revenue Next Year
$10.67
$12.44
P/E Ratio
★ N/A
$102.80
Revenue Growth
8.34
★ 40.45
52 Week Low
$15.88
$18.39
52 Week High
$32.71
$30.96

Technical Indicators

Market Signals
Indicator
BWIN
ACAD
Relative Strength Index (RSI) 57.51 47.88
Support Level $31.70 $20.71
Resistance Level $32.58 $22.92
Average True Range (ATR) 0.11 0.54
MACD -0.04 0.37
Stochastic Oscillator 68.29 89.72

Price Performance

Historical Comparison
BWIN
ACAD

About BWIN The Baldwin Insurance Group Inc.

The Baldwin Insurance Group Inc is an insurance distribution company operating in the United States. The company provides commercial risk management, employee benefits, private risk management, and personal insurance solutions. It operates through three segments: Insurance Advisory Solutions, which focuses on commercial risk management and employee benefits; Underwriting, Capacity & Technology Solutions, which includes managing general agency operations, reinsurance brokerage, captive management, and technology-enabled insurance products; and Mainstreet Insurance Solutions, which offers personal, commercial, and life and health insurance products through community-based distribution channels.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: